PFIZER's THREE-PRONGED OTC GROWTH STRATEGY
This article was originally published in The Tan Sheet
PFIZER's THREE-PRONGED OTC GROWTH STRATEGY includes capitalizing on current brands through line extensions, acquisitions and Rx-to-OTC switches, Exec VP and Chief Financial Officer Hank McKinnell told a meeting of securities analysts Feb. 8 in New York City. "The foundation for future growth is being laid," McKinnell said, "with the initiation of a number of complementary strategies," such as "looking to further capitalize on the strong brand identification of leading products in their category," including Desitin and Unisom.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC